Named For The One Thing It Cannot Do: The Fungi-Nail Deception

A product called “Fungi-Nail,” sold in the foot-care aisle, plastered with “Kills Fungus,” is not able to kill nail fungus. According to a class action complaint filed in the Northern District of Illinois, Arcadia Consumer Healthcare Inc. knew this, admitted it in fine print, and kept the name anyway.

The Non-Financial Ledger

The harm here is quiet and personal. A person with chronic nail fungus walks into a Walgreens, finds a product literally named for their exact problem, reads “Kills Fungus” in bold letters, and trusts it. They apply it night after night, expecting relief, and nothing happens.

The plaintiff, an Illinois woman from Machesney Park, applied the liquid regularly for several months. Her nail fungus never improved because, as the complaint states, the product “was in fact proven to not kill nail fungus.” That is time lost, a condition left untreated, and trust spent on a promise the manufacturer knew it could not keep.

The betrayal is sharpened by design. Consumers were told to look for a “trustworthy” brand name and a clear claim, then quietly contradicted on a panel the company knew shoppers rarely read. The people harmed did nothing wrong; they simply believed the label.

Legal Receipts

The following passages are taken verbatim from the class action complaint. They are the case in the plaintiff’s own words.

“Despite the name ‘Fungi-Nail,’ which suggests that the products are intended to treat, and effective at treating nail fungus, the products contain fine print on a back label disclaimer indicating that the product is not meant to treat nail fungus, nor is it effective at doing so.”

• This establishes the core contradiction: the brand name promises one thing while the company’s own disclaimer confesses the opposite.
• It documents that the corrective information exists but is deliberately relegated to fine print.

“Defendant was aware that many consumers do not read some of the products’ back label fine print that disclaims the name’s assertion and other front-label representations, and was aware its Fungi-Nail products have no ability to treat nail fungus, yet it proceeded to make those claims on the products’ front labels.”

• This alleges knowledge, not accident. Arcadia is said to have understood both the ineffectiveness and the fact that shoppers skip the fine print.
• It converts the case from a labeling mistake into an intentional strategy of misleading through prominence and omission.

“The statement created a false impression. As Arcadia admits, the product does not kill nail fungus.”

• The complaint asserts this is an admitted fact, not a contested scientific claim.
• It removes the “does it work” debate and centers the case on why the misleading name and claim remain.

“Defendant has made millions of dollars in fraudulent sales to individuals who Defendant told were receiving a product that is capable of treating nail fungus.”

• This quantifies the scale of the alleged harm as reaching into the millions of dollars.
• It frames every affected purchase as a transaction built on a claim the company could not deliver.

Public Deception: The Front Label Versus The Fine Print

The complaint alleges a direct gap between what shoppers saw at eye level and what the company knew and buried. Each claim below is paired with the documented reality.

• The front label reads “Kills Fungus” in white capital letters on a bright red background, while the complaint alleges the product “is not capable of killing nail fungus as represented.”
• The product is named “Fungi-Nail” and placed in the foot-care section, yet a non-front panel states “This product is not effective on the scalp or nails.”
• Some packaging carries “Not for nail or scalp fungus,” but the complaint alleges this language “does not appear on the principal display panel” and is not tied to the front claims by any asterisk or callout.
• The front label states “Clinically Proven to Cure and Prevent Fungal Infections,” reinforcing an impression the disclaimer directly contradicts.
• Arcadia’s own website FAQ addresses “why does the Fungi-Nail labeling say not effective on nails and scalp if it is called Fungi-Nail,” an acknowledgment that the name itself creates confusion.

Legal Minimalism: Complying On Paper While Misleading In Practice

The complaint describes a textbook case of satisfying the letter of a disclosure rule while defeating its purpose. Arcadia did include a disclaimer, but allegedly placed it where it could not do its job.

• The complaint alleges the disclaimer “This product is not effective on the scalp or nails” exists but is not on the principal display panel where consumers actually decide to buy.
• Disclosure requirements exist so buyers can make informed choices at the point of sale; the complaint alleges the qualifying language is “not presented to consumers in a clear and conspicuous manner at the point of purchase.”
• The complaint alleges the fine print “contradicts rather than clearly qualifies” the message created by the name and front claims, meaning it functions as cover rather than correction.
• Under the express warranty claim, the complaint argues any disclaimer is ineffective under 810 ILCS 5/2-316(1) because it “conflicts with the specific affirmations on the front label” and “is not clear and conspicuous.”

Profit-Maximization At All Costs

The complaint alleges Arcadia made a conscious choice to keep a misleading name because it drives sales. The harm to consumers was, per the filing, a known and accepted cost of that strategy.

• The complaint states Arcadia “knew the Product does not kill nail fungus yet has refused to change the ‘Fungi-Nail’ name or add a clear front-label disclosure,” and “chose to keep the misleading message to drive sales.”
• It alleges the company “could have selected accurate front-label wording but chose not to.”
• The complaint states Arcadia “has made millions of dollars in fraudulent sales.”
• The named plaintiff paid approximately $13 for a one-ounce bottle, a figure multiplied across “hundreds of thousands of consumers” alleged in the complaint.
• The complaint alleges Arcadia “formulated or controlled the Product, selected or approved its active ingredients, controlled the Product’s labeling,” placing full responsibility for the naming and claims on the company.

The Contractor Shield: Selling Through Retailers

Arcadia does not sell directly to most shoppers; it sells to retailers for resale. The complaint navigates this structure to hold the manufacturer accountable for the label it designed.

• The complaint states Arcadia “sells to retailers for resale certain healthcare products” and that Fungi-Nail is “sold by dozens of retailers throughout Illinois and across the United States.”
• The plaintiff purchased the product from a Walgreens, meaning the retailer sat between the consumer and the manufacturer who designed the challenged label.
• The complaint pre-empts a liability gap, alleging privity is satisfied because purchases were “from Defendant or its authorized retailers acting as Defendant’s agents,” and alternatively that the plaintiff is an “intended third-party beneficiary” of Arcadia’s warranties.
• The pre-suit breach notice was sent to both Walgreens and to Arcadia through its registered agent, closing off the argument that only the store bears responsibility.

Societal Impact Mapping

The alleged deception reaches beyond one bottle into public health trust and consumer economics.

Public Health

• Consumers with chronic nail fungus, a real medical condition, were allegedly induced to treat it with a product that “does not and cannot treat nail fungus,” leaving the condition unaddressed.
• The named plaintiff “continues to suffer from chronic nail fungus” after months of applying the product with “no improvement.”
• The complaint alleges “ordinary consumers lack expertise in microbiology” and cannot know that a treatment for skin fungus may not work on nails, making them dependent on the honesty of the label.

Economic Inequality

• The complaint alleges “hundreds of thousands of consumers” bought the products under a false belief, spreading small individual losses across a large population.
• The suit notes “damages for any individual Class member are likely insufficient to justify the cost of individual litigation,” meaning without a class action these losses “would go un-remedied.”
• Each purchaser paid a “price premium over the Product’s true value” for an attribute the product did not have, a wealth transfer from ordinary shoppers to the manufacturer.

Who Pays? Following The Cost

The complaint traces the financial harm directly from consumers’ wallets into Arcadia’s revenue through the retail chain.

• The cost originated with individual consumers who paid roughly $13 per bottle for a product that “lacked the represented performance attribute.”
• That money flowed through retailers to Arcadia; the complaint alleges Arcadia “received revenues from the challenged sales through its authorized retailers and online channels.”
• The aggregate absorbed by consumers is alleged to be “millions of dollars” across the class, with the amount in controversy stated to exceed $5,000,000.
• Untreated nail fungus leaves the underlying health cost with the consumer, who “expects to purchase an over-the-counter product for nail fungus in the near future,” meaning further out-of-pocket spending.

The “Cost Of A Life” Metric

This Is The System Working As Intended

The complaint describes a design that exploits how retail works and how disclosure rules can be technically satisfied without informing anyone. The structure, not a glitch, produced the harm.

• The complaint alleges Arcadia relied on the documented fact that “many consumers do not read some of the products’ back label fine print,” turning a known consumer habit into a marketing shield.
• It alleges the disclaimer was placed off the principal display panel and untied to the front claims, satisfying a minimal disclosure while defeating its informative purpose.
• The complaint notes individual damages are too small to litigate alone, meaning the harm was structured to stay below the threshold where any single buyer would fight back.
• Despite an FAQ on its own website acknowledging the name causes confusion, the complaint alleges Arcadia “has refused to change the ‘Fungi-Nail’ name,” showing the challenged conduct persisted even after being questioned.

The Settlement Isn’t Justice

No settlement has been reached in this newly filed case, but the complaint identifies structural reasons why money alone would not fix the problem. The plaintiff explicitly demands changes to the label itself.

• The complaint seeks injunctive relief “requiring clear and conspicuous front-label disclosure that the Product does not kill nail fungus,” recognizing that refunds do not stop future shoppers from being misled.
• The plaintiff states she “cannot determine from the current front label whether the product has been corrected, reformulated, or remains ineffective,” so damages without a labeling fix leave the deception in place.
• The complaint requests “corrective advertising as appropriate,” acknowledging that undoing the false impression requires more than paying back individual buyers.
• Because the challenged name and claims remain on shelves, any purely financial resolution would allow the same conduct to continue generating “millions of dollars in fraudulent sales.”

What A Legitimate Fix Looks Like

The core structural failure this case exposes is that a prominent front-label promise can be legally “corrected” by fine print no one is expected to read. The following is editorial analysis, not a finding of the source document.

Regulatory Track

• The FTC and FDA should require that any product named after a condition it cannot treat carry a correction on the principal display panel, in the same prominence as the claim, not the back panel.
• Regulators should treat a disclaimer that “contradicts rather than clearly qualifies” a front-label claim as a deceptive practice by default, closing the fine-print loophole this case describes.
• As a general industry standard, over-the-counter health products should be required to state clearly on the front which conditions they do and do not treat.

Legislative Track

• Illinois lawmakers should strengthen the Consumer Fraud and Deceptive Business Practices Act (815 ILCS 505) to explicitly bar product names that assert efficacy against a condition the manufacturer knows it cannot treat.
• Legislation should require that qualifying disclosures be tied to the specific front-label claims they modify, by asterisk or callout, to be legally effective.
• Statutory damages provisions should be preserved and strengthened so that low-dollar consumer harms remain economically viable to litigate, since this case shows they otherwise “go un-remedied.”

Corporate Governance Track

• Arcadia’s board should mandate that any product name and front-label claim be reconciled with the product’s actual documented efficacy before sale, with sign-off from a compliance officer independent of marketing.
• The company should implement a policy requiring that known consumer confusion, such as the issue its own FAQ acknowledges, trigger a mandatory label review rather than a website explanation.
• Executive compensation tied to sales of the Fungi-Nail line should be reviewed against the deceptive-labeling exposure the product created.

What Now?

Direct your attention to Arcadia Consumer Healthcare Inc., headquartered in Bridgewater, New Jersey, the entity that designed and controls the challenged label.

• Watchlist: The Federal Trade Commission handles deceptive advertising complaints and accepts consumer reports at reportfraud.ftc.gov.
• Watchlist: The FDA regulates over-the-counter antifungal drug claims and accepts reports on misleading health product labeling.
• If you bought a Fungi-Nail product in Illinois believing it treats nail fungus, document your purchase and check whether you qualify as a class member.
• Share the front-label-versus-fine-print reality with people you know; the complaint’s core allegation is that this deception survives on shoppers not reading the back.
• Support local consumer-protection legal aid and organize to demand front-label honesty standards from your state representatives.